Characteristics of transplantation in the different conditioning intensity groups
| Parameter . | MAC (n = 165) . | RIC (n = 143) . | NMAC (n = 88) . | P . |
|---|---|---|---|---|
| Year of allogeneic HCT | ||||
| Before 2004 (2000-2003) | 87 (53%) | 46 (32%) | 32 (36%) | < .001 |
| After 2004 (2004-2009) | 78 (47%) | 97 (68%) | 56 (64%) | |
| HLA match | ||||
| HLA-identical sibling | 66 (40%) | 37 (26%) | 26 (30%) | .121 |
| Unrelated well HLA-matched | 55 (33%) | 69 (48%) | 44 (50%) | |
| Unrelated partially matched | 29 (18%) | 26 (18%) | 13 (15%) | |
| Unrelated mismatched | 7 (4%) | 5 (3%) | 1 (1%) | |
| Unrelated matching to be defined | 8 (5%) | 6 (4%) | 4 (5%) | |
| Donor/recipient sex match | ||||
| Male/male | 59 (36%) | 64 (45%) | 28 (32%) | .359 |
| Male/female | 37 (22%) | 34 (24%) | 25 (28%) | |
| Female/male | 36 (22%) | 22 (15%) | 15 (17%) | |
| Female/female | 30 (18%) | 21 (15%) | 16 (18%) | |
| Donor/recipient CMV serostatus | ||||
| Positive/positive | 42 (25%) | 38 (27%) | 23 (26%) | .753 |
| Positive/negative | 20 (12%) | 17 (12%) | 9 (10%) | |
| Negative/positive | 57 (35%) | 36 (25%) | 27 (31%) | |
| Negative/negative | 41 (25%) | 48 (34%) | 25 (28%) | |
| Missing | 5 (3%) | 4 (3%) | 4 (5%) | |
| Graft source | ||||
| BM | 46 (28%) | 28 (20%) | 13 (15%) | .039 |
| Peripheral blood stem cells | 119 (72%) | 115 (80%) | 75 (85%) | |
| Conditioning regimens | ||||
| MAC | ||||
| CY/TBI | 90 (55%) | 0 | 0 | |
| BU/CY | 38 (23%) | 0 | 0 | |
| Bu/MEL | 6 (4%) | 0 | 0 | |
| FLU/MEL | 4 (2%) | 0 | 0 | |
| FLU/BU | 15 (9%) | 0 | 0 | |
| MEL 200 | 1 (1%) | 0 | 0 | |
| RIC | ||||
| BU/CY-low dose | 0 | 2 (1%) | 0 | |
| FLU/MEL-low dose | 0 | 44 (31%) | 0 | |
| FLU/BU-low dose | 0 | 49 (34%) | 0 | |
| CY/VP16 ± BU | 0 | 11 (8%) | 0 | |
| FLU/ATG | 0 | 1 (1%) | 0 | |
| BEAM + similar | 0 | 17 (12%) | 0 | |
| TBI based-RIC per center | 0 | 3 (2%) | 0 | |
| TBI-low dose-RIC per center | 0 | 7 (5%) | 0 | |
| NMAC | ||||
| TBI based | 0 | 0 | 4 (5%) | |
| TBI-low dose | 0 | 0 | 29 (33%) | |
| FLU/CY | 0 | 0 | 42 (48%) | |
| Others | ||||
| Other/unspecified | 11 (7%) | 9 (6%) | 13 (15%) | |
| TBI in conditioning | 90 (55%) | 15 (10%) | 33 (38%) | < .001 |
| ATG at conditioning regimen or GVHD prophylaxis | ||||
| ATG at conditioning regimen | 27 (16%) | 40 (28%) | 21 (24%) | .046 |
| GVHD prophylaxis | ||||
| FK506 + MTX ± other | 77 (47%) | 50 (35%) | 14 (16%) | < .001 |
| FK506 ± other | 22 (13%) | 45 (31%) | 20 (23%) | |
| CsA + MTX ± other | 50 (30%) | 20 (14%) | 5 (6%) | |
| CsA ± other | 13 (8%) | 26 (18%) | 45 (51%) | |
| Median Follow-up of survivors, mo (range) | 39 (3-108) | 41 (3-87) | 59 (12-99) |
| Parameter . | MAC (n = 165) . | RIC (n = 143) . | NMAC (n = 88) . | P . |
|---|---|---|---|---|
| Year of allogeneic HCT | ||||
| Before 2004 (2000-2003) | 87 (53%) | 46 (32%) | 32 (36%) | < .001 |
| After 2004 (2004-2009) | 78 (47%) | 97 (68%) | 56 (64%) | |
| HLA match | ||||
| HLA-identical sibling | 66 (40%) | 37 (26%) | 26 (30%) | .121 |
| Unrelated well HLA-matched | 55 (33%) | 69 (48%) | 44 (50%) | |
| Unrelated partially matched | 29 (18%) | 26 (18%) | 13 (15%) | |
| Unrelated mismatched | 7 (4%) | 5 (3%) | 1 (1%) | |
| Unrelated matching to be defined | 8 (5%) | 6 (4%) | 4 (5%) | |
| Donor/recipient sex match | ||||
| Male/male | 59 (36%) | 64 (45%) | 28 (32%) | .359 |
| Male/female | 37 (22%) | 34 (24%) | 25 (28%) | |
| Female/male | 36 (22%) | 22 (15%) | 15 (17%) | |
| Female/female | 30 (18%) | 21 (15%) | 16 (18%) | |
| Donor/recipient CMV serostatus | ||||
| Positive/positive | 42 (25%) | 38 (27%) | 23 (26%) | .753 |
| Positive/negative | 20 (12%) | 17 (12%) | 9 (10%) | |
| Negative/positive | 57 (35%) | 36 (25%) | 27 (31%) | |
| Negative/negative | 41 (25%) | 48 (34%) | 25 (28%) | |
| Missing | 5 (3%) | 4 (3%) | 4 (5%) | |
| Graft source | ||||
| BM | 46 (28%) | 28 (20%) | 13 (15%) | .039 |
| Peripheral blood stem cells | 119 (72%) | 115 (80%) | 75 (85%) | |
| Conditioning regimens | ||||
| MAC | ||||
| CY/TBI | 90 (55%) | 0 | 0 | |
| BU/CY | 38 (23%) | 0 | 0 | |
| Bu/MEL | 6 (4%) | 0 | 0 | |
| FLU/MEL | 4 (2%) | 0 | 0 | |
| FLU/BU | 15 (9%) | 0 | 0 | |
| MEL 200 | 1 (1%) | 0 | 0 | |
| RIC | ||||
| BU/CY-low dose | 0 | 2 (1%) | 0 | |
| FLU/MEL-low dose | 0 | 44 (31%) | 0 | |
| FLU/BU-low dose | 0 | 49 (34%) | 0 | |
| CY/VP16 ± BU | 0 | 11 (8%) | 0 | |
| FLU/ATG | 0 | 1 (1%) | 0 | |
| BEAM + similar | 0 | 17 (12%) | 0 | |
| TBI based-RIC per center | 0 | 3 (2%) | 0 | |
| TBI-low dose-RIC per center | 0 | 7 (5%) | 0 | |
| NMAC | ||||
| TBI based | 0 | 0 | 4 (5%) | |
| TBI-low dose | 0 | 0 | 29 (33%) | |
| FLU/CY | 0 | 0 | 42 (48%) | |
| Others | ||||
| Other/unspecified | 11 (7%) | 9 (6%) | 13 (15%) | |
| TBI in conditioning | 90 (55%) | 15 (10%) | 33 (38%) | < .001 |
| ATG at conditioning regimen or GVHD prophylaxis | ||||
| ATG at conditioning regimen | 27 (16%) | 40 (28%) | 21 (24%) | .046 |
| GVHD prophylaxis | ||||
| FK506 + MTX ± other | 77 (47%) | 50 (35%) | 14 (16%) | < .001 |
| FK506 ± other | 22 (13%) | 45 (31%) | 20 (23%) | |
| CsA + MTX ± other | 50 (30%) | 20 (14%) | 5 (6%) | |
| CsA ± other | 13 (8%) | 26 (18%) | 45 (51%) | |
| Median Follow-up of survivors, mo (range) | 39 (3-108) | 41 (3-87) | 59 (12-99) |
CY indicates cyclophosphamide; BU, busulfan; TBI, total body irradiation; Flu, fludarabine; MEL, melphalan; BEAM: carmustine, etoposide, cytarabine, melphalan; VP-16, etoposide; ATG, antithymocyte globulin; MTX, methotrexate; CsA, cyclosporine A; and FK506, tacrolimus.